Drug Co. Patent Agreements Problematic for FTC and Consumers

The U.S Court of Appeals for the 11th Circuit reopened the doors for drug companies seeking to keep cheaper generic drugs off the market. Brand name companies can now pay generic drug manufacturers to drop patent challenges, which the FTC says is unfair to consumers. The court found the FTC overstepped its authority when it banned such agreements in the 1990s. Marc Kaufman, The Washington Post 04/25/2006 Read Article: The Washington Post